Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBIT: 2022-2025

Historic EBIT for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$34.0 million.

  • Taysha Gene Therapies' EBIT fell 31.38% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 16.36%. This contributed to the annual value of -$91.5 million for FY2024, which is 26.26% down from last year.
  • Taysha Gene Therapies' EBIT amounted to -$34.0 million in Q3 2025, which was down 27.18% from -$26.8 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year EBIT high stood at -$16.2 million for Q4 2023, and its period low was -$54.0 million during Q4 2022.
  • In the last 3 years, Taysha Gene Therapies' EBIT had a median value of -$21.4 million in 2025 and averaged -$22.4 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 69.90% in 2023, then plummeted by 59.37% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' EBIT (Quarterly) stood at -$54.0 million in 2022, then skyrocketed by 69.90% to -$16.2 million in 2023, then dropped by 22.69% to -$19.9 million in 2024, then plummeted by 31.38% to -$34.0 million in 2025.
  • Its EBIT was -$34.0 million in Q3 2025, compared to -$26.8 million in Q2 2025 and -$21.4 million in Q1 2025.